FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016183786> ?p ?o ?g. }

• W2016183786 endingPage "342" @default.
• W2016183786 startingPage "325" @default.
• W2016183786 abstract "The peripheral conversion of steroid precursors into biologically active forms can be a major source of steroid synthesis, and these steroids support the growth of hormone-dependent diseases. The 17β-hydroxysteroid dehydrogenase (17β-HSD) enzyme family is involved in the biosynthesis of active steroids and its inhibition constitutes an interesting approach for treating estrogen- and androgen-dependent cancers. We previously found that a compound formed by the introduction of a spiro-γ-lactone at position 17 of estradiol (E2) produces a significant inhibition of type 2 17β-HSD. To optimize the inhibitory potency of such compounds, we synthesized a series of estradiol derivatives bearing a lactone on the D-ring and tested their ability to inhibit the type 2 17β-HSD transformation of 4-androstenedione into testosterone. The results of our structure–activity relationship study determined the importance of the 17β-orientation of the oxygen atom. Indeed, the 17β-O-isomer of spiro-γ-lactone-E2 is a much more potent inhibitor than the 17α-O-analog (respectively 85 and 9% of inhibition at 1 μM). The carbonyl function is essential since the percentage of inhibition shifts from 85 to 30%, 15, or 3%, when the carbonyl group is transformed into a hydroxyl, a methoxy or a methylene (cycloether) group, respectively. Our results lead us to realize the importance of the spirolactone versus the C17β-O/C16β lactone (respectively 32 and 2% of inhibition at 0.1 μM, for the same size of lactone ring). The optimal size for the spirolactone was also established to be six members. All the types of substituents (methyl, dimethyl, allyl, propyl, and methoxycarbonyl) that we added on the spiro-δ-lactone moiety decreased the inhibitory activity, suggesting steric restrictions for the space that can be occupied in proximity of the spiro-δ-lactone functionality. 17-(Spiro-δ-lactone)-E2, compound 6, was thus the most potent inhibitor of type 2 17β-HSD with a Ki value of 29±5 nM. This compound reversibly inhibits type 2 17β-HSD in a non-competitive manner." @default.
• W2016183786 created "2016-06-24" @default.
• W2016183786 creator A5015149164 @default.
• W2016183786 creator A5034301403 @default.
• W2016183786 creator A5089269298 @default.
• W2016183786 date "2004-05-01" @default.
• W2016183786 modified "2023-09-24" @default.
• W2016183786 title "Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure–activity relationships" @default.
• W2016183786 cites W1525342509 @default.
• W2016183786 cites W1550877969 @default.
• W2016183786 cites W1852916337 @default.
• W2016183786 cites W1971097859 @default.
• W2016183786 cites W1988284423 @default.
• W2016183786 cites W1988520880 @default.
• W2016183786 cites W1989738395 @default.
• W2016183786 cites W1994324783 @default.
• W2016183786 cites W1996213478 @default.
• W2016183786 cites W1998612781 @default.
• W2016183786 cites W2007977414 @default.
• W2016183786 cites W2020259519 @default.
• W2016183786 cites W2027028221 @default.
• W2016183786 cites W2027381872 @default.
• W2016183786 cites W2028122416 @default.
• W2016183786 cites W2038339127 @default.
• W2016183786 cites W2056594959 @default.
• W2016183786 cites W2061066255 @default.
• W2016183786 cites W2062542404 @default.
• W2016183786 cites W2066846740 @default.
• W2016183786 cites W2080398125 @default.
• W2016183786 cites W2081922333 @default.
• W2016183786 cites W2084074259 @default.
• W2016183786 cites W2088914856 @default.
• W2016183786 cites W2094624406 @default.
• W2016183786 cites W2116838171 @default.
• W2016183786 cites W2127529986 @default.
• W2016183786 cites W2173459804 @default.
• W2016183786 cites W2219851393 @default.
• W2016183786 cites W2400107736 @default.
• W2016183786 cites W2412673684 @default.
• W2016183786 cites W2953381529 @default.
• W2016183786 cites W4245202624 @default.
• W2016183786 cites W4246234200 @default.
• W2016183786 cites W4251040339 @default.
• W2016183786 doi "https://doi.org/10.1016/j.steroids.2004.03.002" @default.
• W2016183786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15219411" @default.
• W2016183786 hasPublicationYear "2004" @default.
• W2016183786 type Work @default.
• W2016183786 sameAs 2016183786 @default.
• W2016183786 citedByCount "47" @default.
• W2016183786 countsByYear W20161837862012 @default.
• W2016183786 countsByYear W20161837862013 @default.
• W2016183786 countsByYear W20161837862014 @default.
• W2016183786 countsByYear W20161837862015 @default.
• W2016183786 countsByYear W20161837862017 @default.
• W2016183786 countsByYear W20161837862018 @default.
• W2016183786 countsByYear W20161837862019 @default.
• W2016183786 countsByYear W20161837862020 @default.
• W2016183786 countsByYear W20161837862021 @default.
• W2016183786 countsByYear W20161837862023 @default.
• W2016183786 crossrefType "journal-article" @default.
• W2016183786 hasAuthorship W2016183786A5015149164 @default.
• W2016183786 hasAuthorship W2016183786A5034301403 @default.
• W2016183786 hasAuthorship W2016183786A5089269298 @default.
• W2016183786 hasConcept C134018914 @default.
• W2016183786 hasConcept C178790620 @default.
• W2016183786 hasConcept C181199279 @default.
• W2016183786 hasConcept C185592680 @default.
• W2016183786 hasConcept C2776317432 @default.
• W2016183786 hasConcept C2776612806 @default.
• W2016183786 hasConcept C2776683971 @default.
• W2016183786 hasConcept C2777164284 @default.
• W2016183786 hasConcept C2777911890 @default.
• W2016183786 hasConcept C2779279991 @default.
• W2016183786 hasConcept C2780378348 @default.
• W2016183786 hasConcept C2780902042 @default.
• W2016183786 hasConcept C2781067048 @default.
• W2016183786 hasConcept C55493867 @default.
• W2016183786 hasConcept C71240020 @default.
• W2016183786 hasConcept C71315377 @default.
• W2016183786 hasConcept C86803240 @default.
• W2016183786 hasConceptScore W2016183786C134018914 @default.
• W2016183786 hasConceptScore W2016183786C178790620 @default.
• W2016183786 hasConceptScore W2016183786C181199279 @default.
• W2016183786 hasConceptScore W2016183786C185592680 @default.
• W2016183786 hasConceptScore W2016183786C2776317432 @default.
• W2016183786 hasConceptScore W2016183786C2776612806 @default.
• W2016183786 hasConceptScore W2016183786C2776683971 @default.
• W2016183786 hasConceptScore W2016183786C2777164284 @default.
• W2016183786 hasConceptScore W2016183786C2777911890 @default.
• W2016183786 hasConceptScore W2016183786C2779279991 @default.
• W2016183786 hasConceptScore W2016183786C2780378348 @default.
• W2016183786 hasConceptScore W2016183786C2780902042 @default.
• W2016183786 hasConceptScore W2016183786C2781067048 @default.
• W2016183786 hasConceptScore W2016183786C55493867 @default.
• W2016183786 hasConceptScore W2016183786C71240020 @default.
• W2016183786 hasConceptScore W2016183786C71315377 @default.
• W2016183786 hasConceptScore W2016183786C86803240 @default.
• W2016183786 hasIssue "5" @default.

• next